Pharmacology · Direct oral anticoagulants (DOACs)

Edoxaban !

A once-daily oral factor Xa inhibitor for atrial fibrillation and venous thrombosis. Half of it leaves through the kidneys, so kidney function guides its use.

Updated 2026-11-01

Class: Direct oral anticoagulants (DOACs)
Enzyme: Coagulation factor Xa
ATC code: B01AF03

Mechanism of action

Edoxaban binds factor Xa directly, without antithrombin, and blocks both free and clot-associated factor Xa. Less factor Xa means less thrombin, so fibrin formation and thrombin-driven platelet aggregation are both suppressed.

Edoxaban binds the active site of factor Xa
Free and clot-associated Xa are blocked
Less thrombin forms, so less fibrin and less platelet activation

Pharmacokinetics

Absorption: Oral bioavailability about 62%; food does not change it. Peak levels 1 to 2 hours after a dose.
Distribution: About 55% bound to plasma proteins, so it is not removed by dialysis in a useful way.
Metabolism: Minimal; only a small part goes through CYP3A4. It is a P-glycoprotein substrate.
Elimination: About half of the absorbed drug leaves unchanged in the urine.

Indications

Prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Atrial fibrillation →
Treatment of deep vein thrombosis, started after at least 5 days of heparin, low-molecular-weight heparin or fondaparinux. Deep vein thrombosis →
Treatment of pulmonary embolism, with the same initial parenteral course. Pulmonary embolism →

Adverse effects

Common

Bleeding: gums, nose, heavy menstrual bleeding, urine
More gastrointestinal bleeding than with warfarin

Contraindications

Active pathological bleeding
End-stage kidney failure
Not recommended: mechanical heart valves, antiphospholipid syndrome; in the United States, also very high kidney function in atrial fibrillation

Key interactions

Potent P-glycoprotein inhibitors (quinidine, dronedarone, erythromycin, ketoconazole, cyclosporine): Raise edoxaban exposure; the regimen is reduced.
Rifampicin: Lowers edoxaban levels; combined use is avoided.
Antiplatelets, NSAIDs, other anticoagulants: Raise the risk of bleeding.

What is monitored

Kidney function before starting and at least yearly
Signs of bleeding and haemoglobin when needed
Routine PT or INR is not useful; drug-calibrated anti-Xa assays exist

Administration and safety

Oral, once a day, with or without food
For people who cannot swallow, tablets can be crushed and mixed with water or applesauce, or given through a gastric tube
In venous thrombosis it is started only after the initial parenteral anticoagulant course
For life-threatening bleeding, four-factor prothrombin complex concentrate may be considered; andexanet is approved for apixaban and rivaroxaban

Nursing care

Check kidney function and body weight before the first dose
Watch for bleeding: black stools, blood in urine, heavy periods, vomiting blood
After spinal or epidural procedures, check for back pain, numbness or weakness
Teach the patient not to stop it on their own and to tell every dentist and surgeon

Pregnancy and breastfeeding

Data in pregnancy are limited; pregnancy is discussed with the treating team before and during use.

Test yourself

Think of the answer, then tap the question to see it.

How is edoxaban started for deep vein thrombosis, compared with rivaroxaban and apixaban?

Edoxaban starts only after at least 5 days of heparin, low-molecular-weight heparin or fondaparinux; rivaroxaban and apixaban can be started straight away.

Which type of bleeding is more common with edoxaban than with warfarin?

Gastrointestinal bleeding; intracranial bleeding, in contrast, is less common.

Why can dialysis not remove edoxaban in a useful way?

Like the other oral factor Xa inhibitors, it is too protein-bound for dialysis to clear it effectively.

Add to my cards (3)

← Back to the class: Direct oral anticoagulants (DOACs)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Edoxaban: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026); eEML - Electronic Essential Medicines List (World Health Organization, 2025); Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 36 (McGraw Hill, 2023).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.